A rare appearance by the firm's Dr. Eyal Taylor shows him saying that what Multikine does is "not carpet bombing, it's smart bombing." In short, the confidence and enthusiasm of the CEL-SCI team featured in the video is contagious.
From an investment perspective, Multikine is entering Phase III trials to determine if CEL-SCI has indeed developed a "smart bomb" to combat head and neck cancer. The data from Phase I and II trials are extremely encouraging, but the stock has lacked consistent news flow and developments. If some if the rumors we are hearing on the street, that may be about to change.
The video reminds us that CEL-SCI has wisely retained the marketing rights of Multikine in both the United States and Europe. The company has also taken steps to protect the Multikine formula by building the private "Cold-Fill" manufacturing facility which we get some glimpses of for the first time in the video.
Based on some of the trading volume increases following the release of the video, it's hard to imagine that investors didn't get excited about CEL-SCI and Multikine after watching it. The company clearly understands the potential value of Multikine to both cancer patients as well as to investors. You don't always see this balanced and focused approach, and that catches our attention as well.
The fact that there are 7,547,400 million shares short right now marks a slight drop and some covering by those who were previously bearish about the stock. 2.43% of the company is owned by insiders while 6.80% is owned by institutions.
In recent days, shares have recovered 19.05% from the sudden drop which occurred last week, but there is still more upside here. Keep your eyes on CEL-SCI, whose market cap is a mere $ 78,000,000. This one could be getting ready to reach higher with some positive news developments... Again.
Disclosure: Author Ray Dirks owns no shares of CVM
The full version of this report can be found here:
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html
News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com
Add to Digg Bookmark with del.icio.us Add to Newsvine
Media Contacts Only:
e-mail: Email Contact
Most Popular Stories
- NSA Defends Global Cellphone Tracking Legality
- Networks Vie for U.S. Hispanic TV Viewers
- Ad Counts Rise in 2013 for Hispanic Magazines
- Apple Wants Samsung to Pay $22M for Patent Dispute Legal Bills
- Starbucks Gets Grinchy; No Gingerbread Lattes for Tampa Customers
- Apple Paid Its Lawyers More Than $60MM to Defeat Samsung in Court
- Shanghai Smog Forces Factory Shutdowns
- US Consumer Borrowing Rose $18.2B in Oct.
- Economic Bright Spots Not a Sure Boost for President Obama
- Jobs Report Brings Cheer As Unemployment Drops to Five-year Low